Home > Neurology > ECTRIMS 2021 > Experimental Treatments > Preliminary data shows positive results of ATA188 for progressive MS

Preliminary data shows positive results of ATA188 for progressive MS

Presented By
Prof. Douglas Arnold, McGill University, Canada

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECTRIMS 2021
Preliminary data of a phase 1, open-label extension (OLE) trial investigating ATA188 for progressive MS showed that the drug was generally well tolerated and drove sustained disability improvement (SDI) in a significant proportion of patients. Moreover, improved magnetisation transfer ratios (MTRs) were observed in patients with SDI, suggesting possible remyelination [1]. Evidence suggests that Epstein-Barr virus is strongly involved with the pathogenesis of MS [2,3]. To this end, the current trial assessed ATA188 as a potential therapy for patients with progressive MS. ATA188 is an investigational, off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy. In total, 25 patients with progressive MS followed a 12-month dose-escalation protocol of ATA188. Hereafter, patients were invited to enter a 4-year OLE period. Prof. Douglas Arnold (McGill University, Canada) presented preliminary data of the study. SDI, based on the Expanded D...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on